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Summary
Glucagon-like peptide (GLP-1) increases insulin secretion but is rapidly degraded (half-life: 2 min
in circulation). GLP-1 analogue, exenatide (Byetta) has a longer half-life (3.3–4 h) with potent
insulinotropic effects but requires cold storage, daily abdominal injections with short shelf life.
Because patients with diabetes take >60 000 injections in their life time, alternative delivery
methods are highly desired. Exenatide is ideal for oral delivery because insulinotropism is glucose
dependent, with reduced risk of hypoglycaemia even at higher doses. Therefore, exendin-4 (EX4)
was expressed as a cholera toxin B subunit (CTB)–fusion protein in tobacco chloroplasts to
facilitate bioencapsulation within plant cells and transmucosal delivery in the gut via GM1
receptors present in the intestinal epithelium. The transgene integration was confirmed by PCR
and Southern blot analysis. Expression level of CTB-EX4 reached up to 14.3% of total leaf
protein (TLP). Lyophilization of leaf material increased therapeutic protein concentration by
12- to 24-fold, extended their shelf life up to 15 months when stored at room temperature and
eliminated microbes present in fresh leaves. The pentameric structure, disulphide bonds and
functionality of CTB-EX4 were well preserved in lyophilized materials. Chloroplast-derived CTB-
EX4 showed increased insulin secretion similar to the commercial EX4 in beta-TC6, a mouse
pancreatic cell line. Even when 5000-fold excess dose of CTB-EX4 was orally delivered, it
stimulated insulin secretion similar to the intraperitoneal injection of commercial EX4 but did not
cause hypoglycaemia in mice. Oral delivery of the bioencapsulated EX4 should eliminate
injections, increase patient compliance/convenience and significantly lower their cost.
Introduction
Peptides, as therapeutic agents, have several advantages in
clinical applications due to their low toxicity and high specificity
(Bellmann-Sickert and Beck-Sickinger, 2010). Recently, the US
Food and Drug Administration (FDA) approved several peptide
drugs including enfuvirtide that inhibits HIV entry into cells,
exenatide that stimulates insulin secretion in patients with type 2
diabetes and several peptides for treatment of cancer (Bellmann-
Sickert and Beck-Sickinger, 2010). Despite these advantages,
therapeutic peptides have several limitations. They are highly
prone to proteolytic degradation during storage or when used for
oral administration (McGregor, 2008) and require parenteral
administration. In addition, these peptides need cold storage due
to short shelf life after purification or chemical synthesis.
Moreover, repeated injections are often needed but this
decreases patient compliance (Hamman and Steenekamp,
2011). Therefore, there is a great need for exploration of less
expensive and patient-friendly drug delivery methods.
Type 2 diabetes is caused by combination of beta cell
dysfunction and insulin resistance (Scheen, 2003). It is predom-
inantly diagnosed in adults and responsible for 90–95% of the
existing diabetic cases (National Diabetes Fact Sheet, 2011).
Surplus production of hepatic glucose and reduced uptake of
glucose also contribute to excess blood sugar levels (Scheen,
2003). The patients with type 2 diabetes exhibit belittled incretin
effect, which requires insulin secretion in response to high
glucose in the blood (Scheen, 2003). Diabetes is a global rising
problem. According to the national diabetes fact sheet 2011, the
total cost associated annually for treatment and management of
diabetes in the United States is $116 billion, whereas the indirect
costs associated with loss of work, disability and other factors are
$58 billion adding up the total cost to $174 billion. The treatment
for diabetes includes either oral drugs (small molecules) with or
without insulin injections (CDC, 2011). Globally, the prevalence
of diabetes is estimated to escalate from 171 million in 2000 to
366 million in 2030 (Davidson, 2009), which could double the
associated costs. Diabetes is a major health and economic burden
on society (Wild et al., 2004), and therefore, the cost of
treatment of diabetes should be addressed.
GLP-1 is a peptide hormone secreted by the L cells of the
intestine that stimulates the secretion of insulin from the pancreas
(Chia and Egan, 2005). It has been shown to play an important
role in increasing the beta cell mass and has potent antidiabetic
effects associated with weight loss (Baggio and Drucker, 2007).
But GLP-1 has a very short half-life of <2 min because it is
degraded by the dipeptidyl peptidase IV (DPP-IV) serum enzyme
into biologically inactive form, thereby lowering the incretin
action of the peptide (Kieffer et al., 1995). Thus DPP-IV resistant
GLP-1 analogues are needed for treatment of the type 2 diabetes.
Exendin-4 is a DPP-IV-resistant analogue of GLP-1 with higher
binding efficacy to the mammalian GLP-1 receptor than GLP-1
and functions as an effective agonist (Young et al., 1999). EX4
modulates the glucose level in a glucose-dependent manner and
increases the sensitivity to insulin and has shown promising
biological activities in vivo for treating type 2 diabetes (Young
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et al., 1999). Exenatide, a synthetic EX4, is the first drug that
carries out the function of incretin to be approved by FDA for
glycaemic control, along with an oral antidiabetic medication.
Exenatide is used in injectable form and requires cold storage and
sterility. In addition, the requirement for multiple injections
decreases patient compliance. Thus, there is a need for alternative
methods of production and delivery of EX4 or other therapeutic
proteins to reduce the cost and increase patient compliance.
Plants are ideal for expression of therapeutic proteins (Arntzen,
2008; Yusibov et al., 2011) The use of plant chloroplasts to
produce therapeutic proteins is emerging as an alternative new
technology to reduce their cost of production by elimination of
purification, cold storage, transportation, sterile delivery and by
extension of their shelf life (Daniell, 2007). The chloroplast
technology integrates transgenes into the chloroplast genome
through homologous recombination (Verma et al., 2008). The
concept offers several advantages including high levels of
expression, proper folding, formation of disulphide bonds and
oligomers, in addition to other post-translational modifications
(Boyhan and Daniell, 2011; Daniell et al., 2009a; Ruhlman et al.,
2007). The maternal inheritance of chloroplast genome and
harvesting leaves before flowering offer important biological
containment strategies (Daniell, 2007). In addition, overcoming
the transgene silencing and position effect through site-specific
recombination minimizes the number of events required for
screening (Verma et al., 2008). A number of therapeutic proteins
have been expressed in plant chloroplasts including insulin-like
growth factor (Daniell et al., 2009b), interferon a2b (Arlen et al.,
2007), coagulation factor IX (Verma et al., 2010), proinsulin
(Ruhlman et al., 2007), antimicrobial peptides (Lee et al., 2011),
human transforming growth factor-b3 (Gisby et al., 2011)
vaccine antigens against viral, bacterial and protozoan pathogens
(Davoodi-Semiromi et al., 2010; Ferna´ndez-San Milla´n et al.,
2008; Koya et al., 2005). However, oral delivery of transplastomic
lyophilized leaf materials, stability of foreign proteins after
prolonged storage at room temperature, ability to deliver
appropriate dosage, consistency and preservation of the integrity
of the heterologous protein and microbial contamination in plant
materials have not yet been investigated.
In this project, we demonstrate that the chloroplast transfor-
mation system and bioencapsulation within plant cells would be
cost-effective for the production and delivery of functional EX4
for treatment of type 2 diabetes.
Results
Creation and characterization of CTB-EX4 transplastomic
lines
CTB-EX4 fusion gene was constructed in the chloroplast trans-
formation vector—pLD, with a GPGP (Gly-Pro-Gly-Pro) hinge
region to minimize steric hindrance of the fused EX4 and furin
cleavage site, RRKR (Arg-Arg-Lys-Arg), for its release into blood
after the fusion protein is internalized into epithelial cells
(Figure 1a). EX4 is a 39-amino acid peptide identified in the
salivary gland of lizard, Heloderma suspectum, and has 53%
homology of amino acid with GLP-1 but it has several distinct
features from GLP-1. N-terminal sequence (His-Gly-Glu) of EX4
(Figure 1a) is resistant to DPP-IV, which rapidly cleaves the
corresponding GLP-1 sequence (His-Ala-Glu) (Doyle et al., 2003).
In addition, C-terminal 9-amino acid sequence of EX4 (Figure 1a),
which is absent from GLP-1, showed biological importance. Its
truncated form, EX4 (1–30), has 10 times less binding affinity to
GLP-1 receptor, which is similar to that of GLP-1 (Doyle et al.,
2003). Many of substrate sequences to endopeptidase are
present in GLP-1 but not in EX4 (Hupe-Sodmann et al., 1995).
These features make the EX4 5500 times more potent GLP-1
receptor agonist than GLP-1 (Davidson, 2009). Therefore, EX4
was chosen for expression in plant chloroplasts. The fusion gene
was driven by the psbA promoter and 5′ untranslated region
(UTR) to increase expression, and the transcript was stabilized by
the psbA 3′ UTR. The cloned CTB-EX4 fusion gene into the
chloroplast vector was fully sequenced before bombardment. The
putative transplastomic lines were confirmed for transgene
integration using the primer sets, which were able to anneal
specifically to complementary sequences of transgene cassette
and the chloroplast genome. PCR results showed products of
expected sizes as a result of amplification for the defined region
with those primers, 1.65 kb with 3P/3M and 2.1 kb with 5P/2M
(Figure 1b). The site-specific integration of the CTB-EX4 gene was
further confirmed using Southern blot analysis, by probing with
the trnI and trnA flanking sequence. Three HindIII restricted
independent transplastomic lines showed distinct hybridizing
fragments of 9.77 kb (Figure 1c) but not the 7.67-kb fragment
from wild type. Thus Southern blot analysis confirmed the site
specific and stable integration of the transgenes into the
chloroplast genome and homoplasmy.
(a)
(b)
(c)
Figure 1 Evaluation of transgene integration. (a) Schematic
representation of the flanking sequence probe (0.81 kb) and expected
products of the untransformed and transplastomic tobacco chloroplast
genome when digested with HindIII (H). Southern blot probe was
generated using BamHI (B) and BglII (B′). Primers used for transgene
amplification are represented by arrows. Amino acid sequence indicates
the hinge, furin cleavage site and exendin-4 (EX4) (bold letter). Asterisk
represents resistant amino acid against DPP-IV. C-terminal 9-amino acid is
represented by dotted line. (b) The amplification of genomic DNA
fragment with 3P/3M and 5P/2M primer sets to check transgene
integration. M, DNA size marker; WT, untransformed; #5, 6 and 9,
transplastomic lines; Ve, CTB-EX4 containing pLD vector. (c) Southern blot
analysis of CTB-EX4 transplastomic lines showing homoplasmy. CTB,
cholera toxin B subunit.
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Characterization of CTB-EX4 fusion protein expressed in
chloroplasts
To investigate proper translation of the two genes within
chloroplasts, specific antibodies against cholera toxin B (CTB) or
EX4 were used. Both of the antibodies detected the expected
fusion protein of correct size, with no cross-reacting proteins
from untransformed plants. As expected, the detected band
pattern was identical to each other (Figure 2a,b). In addition,
there was no cross-detection of CTB standard proteins by
anti-EX4 antibody (Figure 2b). Each CTB monomer has an
intramolecular disulphide bond. Extensive interactions between
monomers (hydrogen bonds, salt bridges and hydrophobic
interactions) are responsible for the stable pentameric structure
of CTB (Sa´nchez and Holmgren, 2008). But this integrity was
disrupted when reducing agents were included in the extraction
buffer (Figure 2a,b) in which much more monomeric form of
CTB-EX4 was observed, when compared with the extraction
without the reducing agent. Moreover, much less of the fusion
protein was detected in the soluble fraction (Figure 2a,b). The
expression level of the fusion protein was measured quantitatively
using densitometry with known amount of CTB protein to
generate standard curve (Figure S1) at different time points. The
range of expression varied between 7.6% and 14.3% of TLP
(Figure 2c). When the ability of CTB-EX4 fusion protein to bind to
the GM1 receptor was evaluated by GM1 ELISA, the absorbance
values were similar to the CTB positive control. This indicates that
there was proper folding and disulphide bond formation that are
required for the formation of the pentameric structure of CTB-
EX4 (Figure 2d).
Stability, folding, dosage, microbes in lyophilized
materials after prolonged storage
In this study, lyophilized leaf material (6.26 mg of CTB-EX4/g)
was used to deliver appropriate dose of CTB-EX4 by oral gavage
in mice. The content of CTB-EX4 increased 12.5-fold when
compared with fresh leaf material (0.5 mg of CTB-EX4/g)
(Figure 3a), and significant difference in CTB-EX4 intensity was
also observed with equal loading of proteins (equal weight)
from fresh and lyophilized plant materials, in a serial dilution
(Figure 3b), further confirming quantitative studies. The func-
tionality of the lyophilized fusion protein was confirmed using
GM1 ELISA and Western blot assays. In the immunoblots with the
separation range of 10–250 kDa, use of specific polyclonal
antibodies against CTB, EX4 and protective antigen (PA) did not
detect any cleaved fragments for each lyophilized protein in,
providing evidence for their stability. The comparable absorbance
of lyophilized CTB-EX4 to CTB standard was detected (Figure 2d),
and oligomeric forms of CTB were also detected (Figure 3b).
These results indicate that lyophilization does not affect the
assembly of CTB pentamer. In this study, lyophilized leaves stored
up to 4 months at room temperature did not show any degraded
CTB-EX4 protein. To investigate long-term stability of CTB-EX4
further, 10-month-old lyophilized leaf material was compared
with fresh leaves in different conditions using Western blots.
Detected band patterns between fresh and lyophilized protein
samples were identical, including formation of pentamers or
oligomers (Figure 3c,d). Furthermore, the relative band intensity
between CTB-EX4 monomers of lyophilized samples gradually
increased with denaturation (by boiling and/or addition of DTT,
Figure 3d). Relative decrease in the monomer intensity was 100
(+ and +, boiling and DTT, respectively), 66 ( and +), 40 (+ and
) and 7.8% ( and ) (Figure 3d). This demonstrated that
pentameric structure of CTB-EX4 can be stably maintained in
lyophilized state for a long time at room temperature.
To evaluate stability of therapeutic proteins after long-term
storage of lyophilized materials at room temperature, transplas-
tomic lettuce expressing the PA from Bacillus anthracis and CTB-
fused proinsulin (CTB-Pins) were investigated. The reason for
investigating stability of other proteins unrelated to this project is
to evaluate the reproducibility of this concept and to evaluate
stability of much larger size proteins (EX4 is approximately
4.2 kDa, whereas the Anthrax protective antigen is approximately
83 kDa). The soluble PA is stable up to 6 months of storage at
room temperature in lyophilized leaves with no apparent cleaved
products similar to fresh material (Figure 3e). Further study
showed that PA is stable in lyophilized lettuce stored at room
temperature for more than 15 months (data not shown). The
duration of lyophilization did not affect the stability of PA
(Figure 3f) but optimal dehydration was achieved after 72 h of
dehydration. Concentration of both PA and CTB-Pins increased
24-fold in lyophilized leaves when compared with fresh trans-
plastomic materials (Figure 3h). The fold increase in total leaf
proteins was also similar to that of the antigens when compared
with fresh material (Figure 3g). Much more intense band against
PA was observed over the fresh material in Western blots when
equal mass of samples were loaded (Figure 3i), further confirming
quantitative studies.
Bacterial contamination was investigated between fresh and
lyophilized materials to facilitate the safe oral delivery. For
(a) (b)
(c) (d)
Figure 2 Quantification and functional evaluation of CTB-EX4. Western
blot analysis of total leaf homogenate (H, 5 lg) and soluble (S, 5 lg)
protein probed with anti-CTB (a) or anti-EX4 (b) antibodies. Lane 1, 6.25;
2, 12.5; 3, 25 ng of purified cholera toxin B subunit; +, with DTT; ,
without DTT; #6 and 9, CTB-EX4 transplastomic lines; WT, untransformed.
(c) Percentage of CTB-EX4 in the total leaf protein from mature leaves at
different harvesting time. (d) GM1 ELISA for evaluation of CTB-EX4
pentamer assembly. CTB, positive control (10 ng); F, fresh leaf; L,
lyophilized CTB-EX4 transplastomic plant extracts (5 lg of total leaf
protein), respectively; WT, untransformed total leaf protein (5 lg); BSA,
negative control. Data shown are means ± SD of three independent
experiments. CTB, cholera toxin B subunit.
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comparison, commercially available freeze-dried alfalfa was used
as control. While fresh lettuce leaves contained up to approxi-
mately 6000 cfu/g microbes, lyophilized leaves expressing various
foreign proteins had no detectable microbes, when plated on
different growth media (Figure 3j). These investigations show
that highly concentrated therapeutic peptides or proteins could
be delivered orally and safely, when the lyophilized leaf material is
used in capsules (Figure 3k).
Purification and characterization of transplastomic EX4
The CTB-EX4 fusion protein was purified with the anti-CTB
antibody conjugated to protein A beads. The immunoblot assay
against purified CTB-EX4 showed that the first elution fraction
contained the highest amount of fusion protein, and densito-
metric analysis of the first elution of purification revealed 73%
purity (Figure 4a). Silver-stained gel showed a prominent single
band, which corresponded to the CTB-EX4 band in the Western
blot (Figure 4b). Then, furin cleavage assay was performed with
the purified fusion protein to check whether the oral delivery of
proteins would result in cleavage of transplastomic proteins by
the furin enzyme, which is present ubiquitously in all cell and
tissue types in the body (Limaye et al., 2006). The furin-treated
sample revealed the presence of an additional polypeptide at
approximately 12.7 kDa, which represents the size of CTB
monomer subunit (including eight amino acids for the hinge
and furin cleavage site) without EX4 fusion (Figure 4c,d) indicat-
ing the furin cleavage site introduced in the construct was
functional. The silver stain revealed two cleavage products, one at
approximately 12.7 kDa representing the same size of cleaved
CTB product as in Figure 4c and a faint b and at approximately
4.2 kDa representing the EX4 monomer (Figure 4d). These results
confirmed accessibility of furin to its cleavage site to release EX4
after the fusion protein is internalized, by binding to GM1
receptor present on the intestinal epithelium cell surface.
In vitro beta-TC6 pancreatic cell line assay to evaluate
insulin secretion
For functional evaluation of CTB-EX4, purified fusion protein was
incubated with beta-TC6 cells, mouse pancreatic cell line
harbouring GLP-1 receptor on their surface. The role of the
receptor is to amplify glucose-dependent insulin secretion. In a
previous report, beta-TC6 cells increased insulin secretion in
response to glucose concentration in a range from 0 to 20 mM.
The insulin secretion was further enhanced when EX4 was added
within the range of glucose (Masur et al., 2005). In this study,
single glucose concentration (10 mM) was chosen to investigate
the enhancement of insulin secretion by increasing the concen-
tration of CTB-EX4. Direct comparison of commercial EX4 with
purified CTB-EX4 for insulin secretion was inadequate due to a
different molecular weight and a fusion protein. Therefore, the
amount of secreted insulin was compared by increasing concen-
tration of each protein in a dose-dependent manner. Indeed, beta
cells treated with different levels of purity of CTB-EX4 (crude
plant extract, partial and total purification) were evaluated in 88
wells of the insulin ELISA detection kit for optimization and
several independent investigations. We compared insulin secre-
tion between commercial EX4 and purified CTB-EX4 at three
different concentrations using 88 wells of insulin detection kit. All
independent investigations confirmed that purified CTB-EX4
showed insulin secretion activity similar to commercial EX4. For
control, PBS was used instead of CTB alone because commercial
CTB is purified from E. coli and it exists as a monomer. But
(a) (b)
(c) (d)
(e) (f)
(g) (h)
(i) (k)(j)
Figure 3 Lyophilization and characterization. (a) Amount of CTB-EX4
protein in fresh (F) and lyophilized (L) leaves. (b) Western blot analysis
of fresh and lyophilized leaves expressing CTB-EX4. Equal quantity
(50 mg) of fresh and lyophilized material was extracted in same volume
(300 lL) of extraction buffer. Samples were loaded in a serial dilution
as indicated. Western blot analysis with anti-CTB (c) and anti-EX4 (d)
polyclonal antibody to evaluate long-term stability of lyophilized CTB-
EX4 after storage at room temperature for 10 months. F, fresh leaf; L,
10-month-old lyophilized leaf. Total leaf protein (5 lg) was loaded in
each lane. CTB, positive or negative control (20 ng). Samples were
incubated for 10 min with DTT (100 mM) or boiled for 2 min. (e)
Western blot analysis to evaluate stability of protective antigen (PA) in
lyophilized lettuce leaves after storage at room temperature for 2 (1), 4
(2) and 6 (3) months. PA, standard (100 ng); WT, untransformed
lettuce. Total soluble protein (3 lg) was loaded in each lane. (f) Antigen
stability after 3 months of storage and lyophilization for different
durations: (1) 24, (2) 48 and (3) 72 h. Fold increase in total protein (g)
and specific antigen (h) after lyophilization. PA, lettuce transplastomic
plant expressing PA; CTB-Pins, lettuce transplastomic plant expressing
CTB–proinsulin; white bar, fresh material; grey bar, lyophilized material.
(i) Western blot analysis of fresh (F) and lyophilized (L) leaves expressing
PA. Total soluble protein (10 lL) was loaded after equal quantity
(50 mg) was extracted in same volume (300 lL) of extraction buffer. (j)
Microbial burden of leaves expressing PA. 1, fresh leaf; 2, lyophilized
leaf; 3, commercially available freeze-dried alfalfa capsules. (k)
Simplified diagram of capsulation of lyophilized transplastomic leaf
material. Data shown are means ± SD of three independent
experiments. CTB, cholera toxin B subunit; EX4, exendin-4.
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chloroplast-derived CTB-EX4 exists in pentameric form (required
for GM1 binding) or other oligomeric forms as seen in Figure 2a,
b. Therefore, commercial CTB does not serve as an appropriate
control. Insulin secretion reached its maximum at the concentra-
tion of 49 when treated with commercially available EX4 peptide,
which is consistent with a previous report (Baggio et al., 2004).
Likewise, purified CTB-EX4 also increased insulin secretion in a
concentration-dependent manner (Figure 4e). Therefore, this
result indicates similar functionality of EX4 when fused with
CTB expressed in plant chloroplasts or when EX4 was chemically
synthesized.
Oral delivery of lyophilized CTB-EX4 transplastomic
leaves to mice lowered blood glucose level
To investigate the potential for lowering blood glucose level after
oral delivery of lyophilized CTB-EX4 leaf material, blood glucose
level was tested in mice after glucose spike by intraperitoneal
injection. In three previous independent tests, CTB-EX4 showed
its function of lowering glucose level at 90 min after oral gavage,
even without glucose spike (data not shown). For evaluation of
orally delivered lyophilized CTB-EX4 effect on glucose level, blood
glucose levels were measured in mice sera at different time points
using 288 glucose test strips for optimizing this system, with or
without glucose spike and overnight fasting. Glucose measure-
ments were made two or three times for each mouse, for a total
of 288 evaluations of blood glucose levels in mouse sera.
Administered dosage was calculated for each method.
2.39 9 106 lmole of EX4 per mouse (0.01 lg/4.19 kDa, MW
of EX4) was used for i.p. injection, while 1.2 9 102 lmol of
lyophilized EX4-CTB per mouse (208.5 lg/17.2 kDa, MW of CTB-
EX4) was delivered orally. To evaluate glucose-lowering potential
by CTB-EX4, blood glucose level of mice was spiked intraperito-
neally at 60 min after oral gavage. Glucose-lowering effect of
CTB-EX4 reached maximum up to 24.8% reduction at t = 90
(Figure 5a). As the duration after oral gavage increased, the
glucose-lowering effect became smaller (17.3% at t = 120 and
10.1% at t = 150) then finally came down to similar level to
control group at t = 180 (Figure 5a), due to the normal
functional pancreas. To compare the potency of chloroplast-
derived CTB-EX4 with synthetic EX4 peptide in terms of glucose-
lowering effect, mice were subject to same procedure as in
Figure 5a except for i.p. injection of EX4 peptide instead of oral
gavage of CTB-EX4 plant material. Similar glucose-lowering effect
(21.8% reduction) was observed at t = 90 as oral gavage
(Figure 5b). Taken together, oral administration of lyophilized
CTB-EX4 fusion protein produced in plant chloroplast functions
similar to commercial purified EX4 peptide.
Discussion
Type 2 diabetes affects a vast majority of the global population
and requires cost-effective treatment, which otherwise poses the
threat of becoming a pandemic (CDC, 2011). Exenatide, an
injectable insulinotropic agent, demonstrates appreciable antid-
iabetic effects in clinical use among patients with type 2 diabetes
(Lovshin and Drucker, 2009; Riddle et al., 2006) but requires cold
storage and injections. This kind of subcutaneous injection in the
abdomen is very inconvenient for patient because injection sites
should be cleaned with alcohol before use and/or rotated to avoid
or minimize skin irritation (Barnhart et al., 2011). In this study, we
report the expression of CTB-fused EX4 in chloroplast and its
functionality comparable to commercial EX4. This system has
several cost saving advantages associated with production,
purification, storage and transportation when compared with
current methods of production.
Success in using freeze-dried material will depend upon the
stability of foreign proteins, ability to deliver appropriate dosage
and consistency. It is crucial for freeze-dried and stored materials
to preserve the integrity of the heterologous fusion protein
because efficient delivery of the intact protein to the gut-
(a)
(b)
(c)
(e)
(d)
Figure 4 Purification of CTB-EX4 and pancreatic cell line assay. Western
blot (a) and silver staining (b) of purified CTB-EX4. 1-3, CTB standard
proteins of 12.5, 25 and 37.5 ng; 4, wild-type total leaf protein (5 lg); 5,
soluble fraction of CTB-EX4 before purification (5 lg); 6, soluble fraction
of CTB-EX4 after purification (5 lg); 7-9, washed fractions; 10–12, elution
fractions. (c,d) Furin cleavage assay of purified CTB-EX4. CTB, standard
(25 ng); F, without furin; +F, with furin; M, protein size marker; M′,
ultra-low range protein size marker; arrow head, cleaved CTB (12.7 kDa);
arrow, cleaved EX4 (4.2 kDa); dots and numbers, locations of monomer
and oligomers of CTB-EX4. Proteins were resolved on 12% (c) and 16%
(d) of Tricine–SDS–PAGE. (e) Mouse pancreatic cell line assay. Commercial
EX4 (19 = 5 nM) and partially purified CTB-EX4 (19 = 32 nM,
concentration based on the molecular weight of the CTB) were added to
beta-TC6 cells. The graph was normalized to PBS value, which was used as
a negative control. Insulin secretion was compared at three different
concentrations in each group, with duplicate samples, using 88 wells of
insulin detection kit. Data shown are means ± SD (n = 6). CTB, cholera
toxin B subunit; EX4, exendin-4.
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associated lymphoid tissue (GALT) requires proper folding and
assembly (e.g. CTB pentamers to bind GM1) (Boyhan and Daniell,
2011; Limaye et al., 2006; Verma et al., 2010). In this study, we
have shown that fresh and lyophilized materials form CTB
pentamers and the protein profile of monomers, dimers or
pentamers is identical. In the preparation of transplastomic
material for oral delivery, transformed leaves must be powdered
and packaged into capsules. Leaves from fully grown plants were
harvested, freeze-dried, and lyophilized leaves were powdered in
a grinder and stored at room temperature in moisture-free
containers containing silica gel. Machines are now commercially
available for lyophilization and preparation of capsules with
desired particle sizes.
In our hands freeze-dried plant tissues containing vaccine
antigens without CTB fusion proteins were stable for more than
15 months when stored at room temperature at 25 °C. CTB-EX4
was stable in lyophilized tissues throughout the duration of this
study. CTB fusion proteins should be more stable because of
formation of pentamers or aggregates, thereby protecting them
from proteolytic degradation. While there are differences in
expression levels based on leaf age or developmental stage,
therapeutic protein dose should be determined in each batch of
dehydrated ground powder leaves by ELISA or other quantitative
methods. Although the increase in concentration of proteins
expressed in plants during lyophilization is anticipated, this study
reports stability, folding and functionality of therapeutic proteins
bioencapsulated in plant cells. Long-term storage at room
temperature, elimination of cold chain and purification steps
offer the best opportunities to advance low-cost plant-derived
therapeutic proteins.
Nature’s Way has been marketing alfalfa capsules as nutrition
supplement for several decades, illustrating the ability to eliminate
pathogenicmicrobial threats in freeze-dried leaves. The application
of freeze-drying as a source of microbial reduction was therefore
investigated. Resident microbes of freshly harvested leaves were
examined, and the impact of lyophilization on viable colony-
forming units was tested using standard microbiological assays for
pathogenic bacteria, coliforms, yeast andmoulds. For comparison,
commercially available fresh and freeze-dried alfalfa was tested.
While fresh lettuce leaves contained up to 6000 cfu/g of microbes,
lyophilized leaves expressing various foreign proteins had no
detectable microbes when plated on different growth media.
Therefore, the lyophilization process killed microbes present in
fresh leaves. Although lyophilization is used for long-term storage
of some bacteria, such freeze-drying process requires lyoprotective
media components including skim milk, sucrose, trehalose, foetal
calf serum, BSA, etc. and would require low temperature for long-
term storage (Heckly, 1985). However, in this study, no lyoprotec-
tive component was used and the lyophilized transplastomic plants
were stored at room temperature up to 15 months without any
harmful effect on their proteins. Moreover, the stability of the
proteins expressed in transplastomic plants was unaffected even
after 72 h of lyophilization, whereas bacterial lyophilization is
performed for a shorter duration. Therefore, we believe that
differences in the process of lyophilization without any protective
components and long duration of lyophilization should have
eliminated microbes from lyophilized transplastomic plants.
For considerations on safety of oral delivery of peptides, several
important questions must be considered. Multiple doses of daily
use of exenatide has been already approved by the US FDA for
the treatment of type 2 diabetes (Lam and See, 2006), and CTB
was also approved as adjuvant for human vaccines or as a vaccine
antigen (Reed et al., 2009; Ryan and Calderwood, 2000).
Because CTB is immunogenic, there could be potential concerns
on fusion of these two peptides resulting in development of
antibody against EX4. Two recent articles (Odumosu et al.,
2011a,b) investigated the mechanism of CTB fusion proteins
and showed immune suppression of proteins tethered to CTB. For
example, CTB–proinsulin-suppressed dendritic cell (DC) activation
by up-regulating Toll-like receptor 2 (TLR-2). Furthermore, fusion
of CTB to proinsulin was essential for enhancement of immune
suppression, as codelivery of CTB and insulin did not significantly
inhibit biosynthesis of costimulatory factors in dendritic cells
(Odumosu et al., 2011a). Likewise, another autoantigen glutamic
acid decarboxylase fused with CTB strongly inhibited dendritic cell
maturation through down-regulation of major costimulatory
factors and inflammatory cytokine biosynthesis (Odumosu et al.,
2011b). These results show that CTB fusion proteins enhance
immunosuppressive T lymphocytes and do not promote develop-
ment of immunity of tethered proteins. Oral administration of
CTB-linked autoantigens has been shown to induce tolerance by
suppressing development of immune response in several allergic
or autoimmune diseases (Ruhlman et al., 2007; Sun et al., 2010;
Verma et al., 2010). Moreover, immunological tolerance of CTB-
(a)
(b)
Figure 5 Evaluation of functionality of CTB-EX4 in mice after oral gavage
or injection. Glucose (2 g/kg body weight) was injected intraperitoneally at
t = 60 (arrows). (a) Mice were orally gavaged with lyophilized
untransformed (WT) and CTB-EX4 plant leaf materials (EX4) at t = 0. One
outlier was removed from control group because of no glucose spike at
t = 90. (b) Mice were given i.p. injection of PBS (200 lL) and commercial
EX4 resuspended in PBS (0.01 lg in 200 lL) at t = 0. Glucose
measurements were made two or three times for each mouse, for a total
of 288 evaluations of blood glucose levels in mouse sera. Single-factor
ANOVA was performed to test significant difference between groups
statistically. *P < 0.05, **P < 0.01. CTB, cholera toxin B subunit; EX4,
exendin-4.
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linked antigen delivery in human clinical studies (phase I/phase II)
has already been reported. Behcet’s disease is an autoimmune
eye disease caused by abnormal T-cell reactivity to a specific
peptide (BD peptide). In this CTB-based immunotherapy, there
was no evidence for antibody production when CTB-BD peptide
was orally delivered for 12–16 weeks and some patients were
free of this disease up to 24 months (Stanford et al., 2004).
Several studies described earlier show that mucosal tolerance
conferred by CTB is associated with regulatory T cells that secrete
immunosuppressive cytokines, transforming growth factor (TGF-b)
or interleukin 10 (Ma and Jevnikar, 2012; Sun et al., 2010).
Another reason for not developing antibody is probably
because these are native proteins (autoantigens) and a furin
(ubiquitous protease present in all cell/tissue types) cleavage site
was engineered between the CTB and the fusion protein for
prompt cleavage soon after transmucosal delivery. In contrast to
autoantigens, EX4 is a heterologous therapeutic peptide with
53% amino acid homology to human GLP-1. Even though EX4
showed the anti-EX4 antibody formation during the 30-week EX4
clinical trial (Kendall et al., 2005), there are no reports of any
adverse immune response from patients since it was released to
the clinic in 2005, with twice or thrice daily injections. According
to the latest FDA safety update for exenatide prescribed to more
than 6.6 million patients (FDA drug safety information, 2009), no
adverse immune response in patients with type II diabetes
routinely receiving EX4 was reported. However, the Byetta
(exenatide) Summary of Product Characteristics by Eli Lilly
(updated on the eMC on July 5, 2012) reported antibody titres
against exenatide diminished over time and remained low
through 82 weeks in most patients who developed antibodies.
As discussed earlier, CTB-conjugated autoantigens have been
shown to suppress rather than stimulate the immune system,
leading the immune system to tolerate the autoantigens. There-
fore, it is anticipated that conjugation of EX4 to CTB should help
develop tolerance rather than stimulate immune response. There
are several other advantages for using CTB as a transmucosal
carrier. Large mucosal area (approximately 1.8–2.7 m2 against
body weight) (Wilson, 1967) could maximize CTB binding to
human intestinal epithelium (15 000 binding sites per cell)
(Holmgren et al., 1975). The rapid turnover rate of cell-associated
GM1 receptor on the epithelial cell (Fishman et al., 1983) is yet
another advantage. However, if there is a need to investigate
non-receptor-mediated delivery system, protein transduction
domains (PTD) are ideal due to their ability to carry cargo across
the plasma membrane (Wadia and Dowdy, 2002).
The beta-TC6 cell line, a mouse pancreatic beta cell line, was
used for evaluation of the functionality of chloroplast-derived
CTB-EX4 because it exhibits the property of glucose-mediated
insulin secretion, triggered by binding of GLP-1 to its receptor on
cell surface (Hohmeier and Newgard, 2004; Skelin et al., 2010).
This in vitro study revealed that the transplastomic protein
increased the insulin secretion from the pancreatic beta cell line.
The insulin secretion was dose dependent similar to the
commercially available EX4 (Nityanandam, 2011).
Actual goal of this study is to deliver bioencapsulated therapeutic
proteins orally with no need for any purification because purified
EX4 is already available in the clinic for injectable delivery system.
Therefore, animal studies were carried out to investigate the in vivo
functionality of orally administered lyophilized EX4. In the animal
studies, transplastomic CTB-EX4 further confirmed its ability to
reduce blood glucose level similar to injections of commercial EX4
(Figure 5). The mouse strain (C57BL/6) was chosen based on
previous studies on EX4 injections (Stoffers et al., 2000). Nonobese
diabetic mousemodel cannot be used for this study because insulin
secretion is impaired in this mouse model. Other mouse models
used for type 2 (spontaneous, chemically induced, surgical,
transgenic/knockout diabetic mice) are only suitable for long-term
evaluation studies (Srinivasan and Ramarao, 2007). So, blood
glucose level of mice was intentionally spiked to mimic diabetic
symptoms to explore the efficacy of orally delivered EX4 on
hyperglycaemic condition. The amount of EX4 administered orally
tomousewas about 5000 times higher than that of i.p. injections. It
has been well known that EX4 lowers blood glucose levels by
increasing insulin secretion from beta cell in a glucose-dependent
manner, contrasting other insulin secretagogues (e.g, sulfonylure-
as) by which insulin secretion is increased regardless of glucose
concentrations (Kolterman et al., 2003). So the concern about the
risk of hypoglycaemia can be eliminated evenwhen excess amount
of EX4 was administered, owing to the glucose-dependent
insulinotropic mechanism of EX4. This is one of reasons why we
chose the EX4 to be expressed in an encapsulated form using
chloroplasts for oral delivery. Actually, there was no detrimental
effect onmice even whenwe delivered the 5000 times higher dose
of CTB-EX4 over i.p. injection. In a previously reported investigation
(Young et al., 1999), the glycaemic control potency of EX4 was
tested with diabetic db/dbmice in a range from 0.001 to 10 lg of
EX4 permouse. Therewas no harmful effect onmice even in higher
dose injections (1 and 10 lg) in which plasma glucose was rather
maintained at stably lowered level for a longer period than lower
dosages (0.001, 0.01 and 0.1 lg). In addition, all of the bioencap-
sulated CTB-EX4 will not be delivered into the circulatory system
due to a direct passage of gastrointestinal tract and degradation of
nonbioencapsulated CTB-EX4 in stomach. Therefore, lyophilized
and bioencapsulated CTB-EX4 system could provide a convenient
and cost-effective delivery method as an alternative way to replace
current injectable system for the treatment of type II diabetes,
without causing a severe side effect such as hypoglycaemia.
The current cost of exenatide for daily use (twice daily)
exceeding several thousand dollars annually is not available for a
large population in developing countries, earning <$2/day (Bond,
2006). But producing exenatide in the lettuce chloroplast
transformation system should provide a solution to the existing
problem and would significantly lower the cost of incretin
treatment for type 2 diabetes. So, the idea presented in this
study is intriguing and potentially could benefit the lives and
economy of people suffering from type 2 diabetes.
Experimental procedures
Vector construction, transgene integration,
regeneration and evaluation of transplastomic plants
The CTB-EX4 chimeric gene (465 bp) was synthesized with specific
primer sets. One forward primer: DV42 (5′-TTCATATGA
CACCTCAAAATATTACTGATT-3′) and three reverse primers:
R1-EX4 (5′-CATTTGTTTAGATAAATCAGAAGTGAAAGTACCTT-
CAC CATGACGTTTACGCCGGGGCCC-3′), R2-EX4 (5′-CCGTTT
TTTAACCATTCAATGAATA AACGTACAGCTTCTTCTTCCATTTG
TTTAGATAAA-3′), R3-EX4 (5′-AGTTCTAGATCAAGAAGGAGGAG
GAGCACCAGAAGAAGGACCACCGTTTTTTAACCATTC-3′) were
used. The three reverse primers had overlapping sequence for each
other to elongate the coding sequence. The PCR-amplified and
sequence-confirmed fragment was cloned into the chloroplast
transformation vector, pLD. Delivery of chloroplast vector, regen-
eration, evaluation and quantification of transplastomic lines were
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performed according to the previously published methods (Verma
et al., 2008). Immunoblot analyses were carried out with rabbit
anti-CTB polyclonal antibody (GeneWay, San Diego, CA), rabbit
anti-EX4 polyclonal antibody (Abcam, Cambridge, MA) and anti-
PApolyclonal antibody (Ruhlman et al., 2010). Thebinding assay of
functional pentameric form of CTB-EX4 to GM1 ganglioside
receptor was carried out as described previously (Limaye et al.,
2006).
Lyophilization
Crumbled and frozen samples were transported to the lyophilizer
on liquid nitrogen and treated for varying durations of 24, 48 and
72 h. Optimization based on percentage of dehydration was
measured through relative gravimetric analysis. Lyophilization was
carried out with the aid of VirTis BenchTop 6K freeze dryer system
in vacuum at52 °C at 0.036 mBar. The lyophilized leaf materials
were ground in a coffee grinder (Hamilton Beach, Southern Pines,
NC) at maximum speed for 2 min (pulse on 10 s and off 30 s) and
sieved usingmesh (size: 100; Sigma, St. Louis, MO). After that, fine
powder was stored in capsules under moisture-free condition at
room temperature with silica gel.
Evaluation of microbes
Fresh and lyophilized materials were ground under aseptic
conditions, mixed with peptone saline diluents for serial dilutions
to obtain colony count. Nutrient broth agar or Luria–Bertani broth
agar was used for microbial growth for 48–72 h at 37 °C. Colony-
forming unit (CFU) was obtained with means and standard
deviations from two repeats of independent experiments.
Purification of CTB-EX4, furin cleavage and silver
staining
To purify CTB-EX4 fusion proteins, pierce crosslink IP kit (Thermo
Scientific, Rockford, IL) was used according to the manufacturer’s
protocol. The eluted fractions were dialysed against PBS three
times, aliquoted and stored at 20 °C. Furin cleavage assay was
performed as previously described (Munck et al., 1999). Released
CTB fragments and EX4 peptides were detected via immunoblot
using anti-CTB polyclonal antibody and silver stain (Boyhan and
Daniell, 2011), respectively, after resolution in Tricine–SDS–PAGE
gel (Scha¨gger, 2006).
In vitro cell culture assay
The mouse pancreatic cell line, beta-TC6, was cultured in DMEM
(ATCC, Manassas, VA) medium supplemented with 15% heat
inactivated foetal bovine serum, 100 U/mL penicillin and 100 U/
mL streptomycin at 37 °C under 5% CO2 condition. The beta-
TC6 cells were harvested at 70–80% confluence and incubated in
glucose-free Krebs–Ringer bicarbonate buffer for 1 h at 37 °C.
The buffer was then removed, and cells were incubated in Krebs–
Ringer bicarbonate buffer with the various concentrations of
purified CTB-EX4, commercial EX4 (California Peptide Research,
Napa, CA) and glucose (10 mM) for 45 min at 37 °C. PBS was
used as the negative control. The amount of insulin secreted into
the supernatant was determined using the mouse insulin ELISA kit
(Crystal Chem, Downers Grove, IL).
Animal study for evaluation of lowering effect of
CTB-EX4
Ten-week-old female mice (C57BL/6) were purchased from the
(Jackson Laboratory, Bar Harbor, ME). Mice were housed in UCF
animal facility under controlled humidity and temperature con-
ditions. All animal studies were performed according to ethical
standards and protocols approved by the UCF Institutional Animal
Care Use Committee (IACUC). The fine powder of the lyophilized
leaf material expressing CTB-EX4 was resuspended in a ratio of
100 mg to 800 lL of sterilized PBS. Then, of 900 µL of
resuspended solution, 300 µL was given to each mouse
(1.2 9 102 lmol of EX4-CTB/mouse, 15 weeks old). Commer-
cial EX4 was resuspended in PBS and sterilized using 0.2-lm
syringe filter. Mice were given 200 µL of PBS containing EX4
(0.01 lg, 2.39 9 106 lmole of EX4/mouse) and PBS only as
control. For glucose spike in mice, glucose (2 g/kg) was admin-
istered intraperitoneally. Blood was collected from tail vein at 30,
90, 120, 150 and 180 min after or 30 min before oral gavage or
i.p. injection of commercial EX4. Glucose levels were measured
using Accu-Chek (Roche, Indianapolis, IN).
Statistics
Single-factor ANOVA was used for statistical evaluation of data.
Differences with P < 0.05 were considered significant. Data are
presented as the mean ± SD.
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